D. Macey

发表

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy.

G. Denardo, S. Denardo, M. Groch, 1996, Nuclear medicine and biology.

Validation of a dose-point kernel convolution technique for internal dosimetry

A L Boyer, A. Boyer, J. Bayouth, 1995, Physics in medicine and biology.

The measurement of the depth of a point source of a radioisotope from gamma ray spectra.

T. R. Munro, D. Macey, L. Filipow, 1979, Physics in medicine and biology.

Dosimetry of solid tumors.

R. Vessella, R. Meredith, T. Johnson, 1993, Medical physics.

Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy.

K. Lamborn, G. Denardo, S. Denardo, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Planar gamma camera quantitation of 123I, 99mTc or 111In in the liver and spleen of an abdominal phantom.

G L DeNardo, G. Denardo, S. Denardo, 1999, Cancer biotherapy & radiopharmaceuticals.

Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

A Primer for Radioimmunotherapy and Radionuclide Therapy

An Liu, T. Johnson, L. Williams, 2001 .

Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.

K. Lamborn, G. Denardo, S. Denardo, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies

J. McGahan, G. Denardo, S. Denardo, 1987, The International journal of biological markers.

Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.

J. Murray, D. Podoloff, J. Schlom, 1995, Cancer research.

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

J. Schlom, W. Grizzle, E. Partridge, 2001, Cancer biotherapy & radiopharmaceuticals.

Phase II radioimmunotherapy trial with 131I‐CC49 in colorectal cancer

J. Murray, D. Podoloff, J. Schlom, 1994, Cancer.

Dosimetry considerations of bone-seeking radionuclides for marrow ablation.

J. Bayouth, D. Macey, 1993, Medical physics.

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

S. Shen, R. Meredith, A. Lobuglio, 2003, Cancer biotherapy & radiopharmaceuticals.

PHASE II TRIAL OF 131I-CC49 Mab PLUS ALPHA INTERFERON (rIFNα) IN BREAST CANCER

J. Murray, D. Podoloff, J. Schlom, 1994 .

Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer.

G. Denardo, S. Denardo, K. Hisada, 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Design of a Radiolabeled Monoclonal Antibody for Radioimmunodiagnosis and Radioimmunotherapy

G. Denardo, S. Denardo, G. Adams, 1988 .

A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy.

R. Meredith, D. Macey, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.

M. Dimopoulos, J. Bayouth, J. Garlich, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies

G. Denardo, S. Denardo, A. Epstein, 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

RADIOIMMUNOTHERAPY STUDIES IN BREAST CANCER

G. Denardo, S. Denardo, I. Hellstrom, 1992 .

Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

J. Schlom, W. Grizzle, R. Meredith, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.

G. Denardo, S. Denardo, M. Groch, 1993, Nuclear medicine communications.

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

S. Shen, J. Duan, R. Meredith, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunotherapy for Breast Cancer: Treatment of a Patient with I-131 L6 Chimeric Monoclonal Antibody

G. Denardo, S. Denardo, I. Hellstrom, 1991, The International journal of biological markers.

Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).

G. Denardo, D. Macey, 2010, Cancer biotherapy & radiopharmaceuticals.

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.

J. Murray, D. Podoloff, J. Schlom, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer

J. Schlom, S. Shen, R. Meredith, 2004 .

Estimation of Radiation Absorbed Doses to the Red Marrow in Radioimmunotherapy

S. Shen, D. Macey, 1995, Clinical Nuclear Medicine.

Radiation treatment of B cell malignancies with immunoconjugate.

G. Denardo, S. Denardo, D. Macey, 1990, Frontiers of radiation therapy and oncology.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

J. McGahan, K. Lamborn, G. Denardo, 1998, Cancer biotherapy & radiopharmaceuticals.

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.

J. Bayouth, F. Fossella, D. Macey, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

K. Lamborn, G. Denardo, S. Denardo, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Quantitative imaging of holmium-166 with an Anger camera.

J. Bayouth, D. Macey, 1994, Physics in medicine and biology.

Detection Limits in Various Applications of Instrumental Nuclear Activation Analysis.

D. Macey, 1973 .

Determination of oxygen and nitrogen in gases by prompt gamma ray measurement

W. Gilboy, D. Macey, 1971 .

Practical simplifications for radioimmunotherapy dosimetric models

G. Denardo, S. Denardo, S. Shen, 1999 .

Practical determination of organ S values for individual patients for therapy.

G. Denardo, S. Denardo, S. Shen, 1997, Nuclear medicine and biology.

Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients

G. Denardo, S. Denardo, D. Macey, 1988 .

Requirements for a treatment planning system for radioimmunotherapy.

G. Denardo, S. Denardo, M. Hays, 1985, International journal of radiation oncology, biology, physics.

Effect of recombinant α-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer : A phase II trial

J. Murray, D. Podoloff, J. Schlom, 1997 .

A treatment planning program for radioimmunotherapy.

G. Denardo, S. Denardo, D. Macey, 1989, Frontiers of radiation therapy and oncology.

A Primer for Radioimmunotherapy and Radionuclide Therapy

L. Williams, D. Macey, H. Breitz, 2001 .

Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma.

G. Denardo, S. Denardo, M. Unger, 1988, American journal of physiologic imaging.

Development of monoclonal antibody imaging of metastatic prostatic carcinoma

S. Denardo, R. D. White, F. Meyers, 1989, The Prostate.

Comparison of low- and medium-energy collimators for SPECT imaging with iodine-123-labeled antibodies.

G. Denardo, S. Denardo, D. Macey, 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.

A. Boyer, J. Bayouth, R. Champlin, 1995, Medical physics.

A phase I pharmacokinetic, toxicity and dosimetry study of 131I labeled IMMU-4 F(ab')2 in patients with advanced colorectal carcinoma

J. Murray, D. Podoloff, J. Bayouth, 1993 .

Cancer Treatment with Radioactive Labeled Antibodies

G. Denardo, S. Denardo, D. Macey, 1986 .

Real-time monitoring and verification of in vivo high dose rate brachytherapy using a pinhole camera.

J. Duan, I. Brezovich, D. Macey, 2001, Medical physics.

Comparison of three boundary detection methods for SPECT using Compton scattered photons.

G L DeNardo, G. Denardo, S. Denardo, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology.

P. Lundberg, D. Wilcken, D. Macey, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Image resolution in infrared thermography.

R. Oliver, D. Macey, 1972, Physics in medicine and biology.

LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE

C. Hawkey, D. Macey, S. McCarthy, 1977, The Lancet.